Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Clinical trial NCT07383116 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07383116
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non Squamous Non-small Cell Lung Cancer

Start date: 2026-01-15
Primary completion: 2028-04-10
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.